anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A mobile device to provide a medical image based distortion correction mechanism is described. An image analysis application, executed by the mobile device, captures a digital copy of the medical image with a camera component in response to a user action. Distortion(s) associated with the digital copy are identified by processing the digital copy with deep neural network (DNN) model(s). Next, a manual correction description is determined to correct the distortion(s) in relation to the camera component and the medical image. Furthermore, a notification to recapture the digital copy is provided to the user. The notification includes the manual correction description. Additionally, in response to another user action to correct the distortion(s) or a failure to detect the user execute manual correction(s) associated with the distortion(s) within a time period, the distortion(s) within the digital copy are corrected and the corrected digital copy is provided to the user.
Disclosed is a method for facilitating provisioning of health data during emergencies. The method includes receiving a health data associated with an individual from an individual device. Further, the method includes storing the health data in association with an identifier associated with the individual. Yet further, the method includes receiving an indication of a medical emergency associated with the individual. Further, the method includes retrieving the health data associated with the individual based on receipt of the indication of the medical emergency. Further, the method includes receiving a location of the individual from a mobile device, wherein the mobile device is configured to detect the location. Moreover, the method includes identifying at least one professional device based on the location. Further, the method includes transmitting the health data to the at least one professional device.
Polyploids are essential in plant evolution and species formation, providing a rich genetic reservoir and increasing species diversity. Complex polyploids with higher ploidy levels often have a dosage effect on the phenotype, which can be highly detrimental to gametes, making them rare. In this study, offspring plants resulting from an autoallotetraploid (RRRC) derived from the interspecific hybridization between allotetraploid Raphanobrassica (RRCC, 2n = 36) and diploid radish (RR, 2n = 18) were obtained. Fluorescence in situ hybridization (FISH) using C-genome-specific repeats as probes revealed two main genome configurations in these offspring plants: RRRCC (2n = 43, 44, 45) and RRRRCC (2n = 54, 55), showing more complex genome configurations and higher ploidy levels compared to the parental plants. These offspring plants exhibited extensive variation in phenotypic characteristics, including leaf type and flower type and color, as well as seed and pollen fertility. Analysis of chromosome behavior showed that homoeologous chromosome pairing events are widely observed at the diakinesis stage in the pollen mother cells (PMCs) of these allopolyploids, with a range of 58.73% to 78.33%. Moreover, the unreduced C subgenome at meiosis anaphase II in PMCs was observed, which provides compelling evidence for the formation of complex allopolyploid offspring. These complex allopolyploids serve as valuable genetic resources for further analysis and contribute to our understanding of the mechanisms underlying the formation of complex allopolyploids.
Embodiments of the invention generally provide methods and compositions for producing polyvalent antigens, disease-specific antigens, transglutaminase-reactive compounds, and recombinant transglutaminases. A method of producing a cross-linked compound by a biological agent is also provided. The invention provides a method for producing a cross-linked antigen and a method of using cross-linked products as antigens to immunize animals and induce strong immune responses. In addition, a method of producing an antigen specific for Alzheimer's disease is provided. Further, a method of producing a polyvalent antigen for two or more diseases is provided. Thus, compositions of antigens are prepared and provided to immunize animals and induce strong immune responses. The invention provides purified recombinant transglutaminases reactive to a broad range of compounds and exhibit broad substrate activity. Additionally, the invention provides a method of attaching one or more amino acid residues to a compound to be reactive with transglutaminase, even for transglutaminase non-reactive compounds.
Disrupted vaginal microbiomes are associated with a number of poor reproductive outcomes, including infertility, miscarriage, premature rupture of membranes, preterm labor and delivery, delivery of a low birthweight baby, and maternal infections (chorioamnionitis, endometritis). A healthy vaginal microbiome is typically thought to be one that is dominated by one of several Lactobacillus species, such as L. crispatus, L. gasseri, or L. jensenii. Several studies have shown that non-lactobacilli-dominant biomes are associated with poor in vitro fertilization or intrauterine insemination outcomes. Fewer studies have examined fertility in the home setting, and none to date has asked whether improving the vaginal microbiome (VMB) could increase fertility. This study addresses both. By assessing the VMB before and after using a vaginal care system which supports a healthy VMB, we will be able to examine whether there are associations between VMB composition and infertility, and whether shifting the VMB toward a lactobacillus-dominant state is able to improve chances of conception.

In this study, women will either follow routine care (control) or routine care plus the vaginal care system and fertility lubricant (intervention) for 3 months or until becoming pregnant, whichever comes first. In addition to tracking conception rates during those 3 months, we will follow women for an additional year following completion of the 3-month timeframe. If any woman is pregnant at the one-year mark, her pregnancy will be followed until delivery (or early termination) to track delivery outcomes and adverse events.
At least 1000 FH patients will be recruited from 30 outpatient clinics representing the 12 Nuts statistical Regions in Turkey proportional to the 2015 Turkey's Population distribution. Both HeFH and HoFH patients are eligible for enrollment. Sites specialized on cardiology, internal medicine, and endocrinology were invited by the Turkish Society of Cardiology. The primary objective of this cross-sectional study, is to detect the clinical status and management of the patients diagnosed with FH in Turkey. The secondary objectives are; to detect the pattern of clinical presentation, to know the medication use, to define the clinical response to LLT, to evaluate the attainment of LDL-cholesterol goals and to identify resistance and/or intolerance to LLT. Defining the CV risk factors and approach to these factors by the physicians, and comparing the attitudes in different specialty groups (cardiology, endocrinology and internal medicine) are also among the secondary objectives of the registry. Eligibility for screening was defined as having LDL-cholesterol levels \> 160 mg/dl either as on treatment or untreated values. Centers may enroll both incident and prevalent patients. The inclusion criteria included age \> 18 years and being diagnosed as possible FH. The possible FH was defined as having a total score of \> 2 according to Dutch lipid clinic network (DLCN) criteria. Patients with triglyceride levels \> 400 mg/dl or secondary hyperlipidemia (ie, untreated hypothyroidism, nephrotic syndrome, cholestasis, etc..) will be excluded from the study. Two different data sets will be collected for A-HIT2. The physicians will complete electronic case report forms for each patient Patients will also complete a short survey to assess the level of disease awareness. This survey is also designed to give information on the patients' perceptions and knowledge on cholesterol, its harm, and LLT. All data will be collected in a single visit. Data verification will be based on the source document control of 5% sample randomly selected per center.
Paying attention to the relationship between inflammatory diseases and cytokines, attempts are made to search for a functional antibody endogenously inhibiting cytokines. A mouse is immunized with a human peripheral monocyte fraction and cytokine inhibitory effects of the thus obtained antibodies are examined. As a result, it is confirmed that, among these antibodies, an antibody &num;33 inhibits the production of a large number of typical inflammatory cytokines. At the same time, the IL-10 production promoting effect of the antibody &num;33 is examined. As a result, it is found out that the antibody &num;33 shows an effect of facilitating the production of IL-10 but has no activity of inducing excessive IL-10 production. It is further clarified that the antigen of this hopeful antibody is CD61. Therefore, it is expected that the application of the anti-CD61 antibody to the treatment of inflammatory diseases would enable the provision of a drug having a reliable efficacy and a high safety.
An instrumentality for promulgating the cryoprecipitation of fibrinogen from a blood product. The instrumentality contemplates a container for the blood product, an apparatus for creating the fibrinogen within the container and a method of manipulating the container within the apparatus and subsequently after fibrinogen has been formed. The apparatus includes a receiver within which the container is supported, a motion transfer device for the receiver to impart motion to the container while simultaneously subjecting the container to a temperature differential to cause heat transfer. The motion imparted to the container results in a thin coating of the blood product being disposed on an interior surface of the container which, in turn, is exposed to a heat transfer fluid through the wall of the container. Successive coatings placed on an interior of the container are timed such that each coating is placed on a previous coating that has changed phase. Flexure of the container after the contents of the container have been frozen can occur by providing a vacuum within the container causing an implosion of frozen material. Subsequent phase change back to a liquid and then a second freeze/thaw followed by centrifugation causes a cryo-fraction to be precipitated therefrom. The container within which the blood product is housed includes an opening for admission of the blood product therewithin, an outlet for extraction of fibrinogen and access to a source which can provide a pressure differential vis a vis the interior and exterior of the container. Information of the temperature profile within the container may also be provided.
Silicon rubber comps. contg. a curing catalyst are characterised by a content of 0.1-5 wt.% with respect to silicon rubber, of a Harada complex cpd. of formula 1/2R2SnA2.R2SnO (where R is C1-8 alkyl and A is a C1-22 carboxylic acid residue). Curing is effected at between room temp. and 100 degrees C, with stirring.
The recommended dose of ribavirin capsules in patients 18 years of age and older depends on the patient’s body weight. The recommended dose of ribavirin is provided in TABLE 6.

The recommended duration of treatment for patients previously untreated with interferon is 24 to 48 weeks. The duration of treatment should be individualized to the patient depending on baseline disease characteristics, response to therapy, and tolerability of the regimen. (See Description of Clinical Studies and ADVERSE REACTIONS). After 24 weeks of treatment, virologic response should be assessed. Treatment discontinuation should be considered in any patient who has not achieved an HCV RNA below the limit of detection of the assay by 24 weeks. There are no safety and efficacy data on treatment for longer than 48 weeks in the previously untreated patient population.

In patients who relapse following non-pegylated interferon mono-therapy, the recommended duration of treatment is 24 weeks. There are no safety and efficacy data on treatment for longer than 24 weeks in the relapse patient population.

  


Ribavirin may be administered without regard to food, but should be administered in a consistent manner with respect to food intake. (See CLINICAL PHARMACOLOGY).
The purpose of the present invention is to provide a composition for promoting cartilage regeneration and a method for promoting cartilage regeneration, which promote cartilage regeneration. The present invention relates to a composition for promoting cartilage regeneration, which is characterized by containing a flavonoid represented by the following general formula (1) as an active ingredient. (in the following formula, R 1 、R 2 、R 3 、R 4 And R 5 Each independently represents a hydrogen atom or a hydroxyl group. R 6 Represents a hydroxyl group or an alkoxy group having 1 to 2 carbon atoms. R 7 And R 8 One of them represents a hydrogen atom, and the other represents a hydroxyl group or an alkoxy group having 1 to 2 carbon atoms. The dashed lines indicate that bonds may or may not be formed. )
Supervised exercise. The intervention will be a free 12-week, small-group (\~10 people) exercise program supervised by specially trained instructors, combining two weekly 1h sessions of moderate to high intensity aerobic and strength exercise. Participants are encouraged to undertake an additional group-based walking exercise guided by target heart rates.
The desired function of a cosmetic material is so-called make-up effect and the skin care effect of conditioning skin. The comprehensive anti-aging cosmetics can be provided. Although cosmetics advertised with anti-aging function are already on the market, the anti-aging function is usually from moisturizing ingredients. However, the cosmetics having an effect of improving wrinkle or a real feeling after using them are not common. In order to endow this function, the present invention provides a cosmetic material which adopts the water-soluble polymer using 2-methacryloyloxyethyl phosphorylcholine as constitution unit to keep the active ingredients in the cosmetic. The make-up effect can be improved by making the active ingredients continuously act on the skin. Furthermore, the active ingredients can permeate into skin and improve the skin by mixing with the hydrogenated soybean phospholipids with high concentration and the liposomes with small particle radius. The means of this invention is a cosmetic material characterized by containing water-soluble polymers using 2-methacryloyloxyethyl phosphorylcholine as constitution unit, lecithins and/or liposomes, and vitamins.
The participants started OPR 6 weeks after TORS. Each exercise was repeated 10 times, 1-3 cycles per day, 3-5 sessions per week at their home and performed for 3 months. Patients were supervised by physical therapist once a week for 30 minutes.
The postoperative mobilization of children in this group will be provided in the corridor, which is the routine of the relevant service, and they will be prevented from seeing the interactive floor before mobilization. Children in this group will be allowed to use the interactive floor in their mobilization after their 3rd mobilization.
The present invention provides lipid nanoparticles etc. containing cationic lipids for delivering drugs containing cationic lipids that make it easy to introduce nucleic acids into cells etc., for example. The cationic lipids are represented by: formula (I) (in the formula: R 1  and R 2  are the same or different alkenyls etc.; X 3  does not exist, or is an alkyl etc.; X 1  and X 2  are hydrogen atoms, or together form a single bond or an alkylene; Y 1  does not exist, or is an anion; L 1  is a single bond etc.; and R 3  is an alkyl etc.); and formula (II) (in the formula: R 4  and R 5  are the same or different alkenyls etc.; X 4  and X 5  are hydrogen atoms, or together form a single bond or an alkylene; X 6  does not exist, or is an alkyl etc.; Y 2  does not exist or is an anion; a and b are the same or different integers from 0 to 3; L 4  is a single bond etc.; R 6  is an alkyl etc.; L 2  and L 3  are -O-, -CO-O- or -O-CO-).
Hair thinning affects upwards of 50% of women by age 50, impacting their social-emotional wellbeing. It is a condition now thought to be driven by a multi-factorial etiology, including diet and nutrition. Women following vegan, vegetarian, or other plant-based diets have specific needs for nutrients traditionally sourced from animals, which could affect hair health. To support hair growth and quality in women following a plant-based diet, a novel vegan nutraceutical (Nutrafol Women's Vegan Capsules, Nutraceutical Wellness, Inc., New York, NY) was evaluated for its ability to support hair health. The objectives of this 6-month, multi-site, single-blind prospective clinical study was to evaluate the safety and efficacy of the nutraceutical to improve hair growth and quality in women consuming a plant-based diet. The primary endpoint in this study was an increase in terminal hair count at day 180 compared with baseline, as assessed through phototrichogram analysis. Ninety-five subjects completed the study. Daily intake of the nutraceutical resulted in a significant increase in the number of terminal hairs at day 90 (P<0.01) and day 180 (P<0.01). There was also an increase in total hair counts (P<0.01), the terminal-to-vellus ratio (P<0.01), and a decrease in shedding (P<0.01). Global Investigator Ratings revealed improved hair growth (P<0.00001) and overall quality (P<0.00001). In-person hair strength and brittleness assessments significantly improved as well (P<0.01 for both). A significant proportion of subjects reported improved hair quality, appearance, texture, and volume. Hair problems affecting the quality of life of the subjects were also reported as improved. This study demonstrated significant improvements in hair growth and quality in a plant-based population with a vegan nutraceutical. ClinicalTrials.gov Identifier: NCT05332743. J Drugs Dermatol. 2024;23(8):661-668.  doi:10.36849/JDD.8421.
Reiki, an energy-based practice based in Japanese culture, consists of the words "rei" meaning "Spirit" and "ki" meaning "universal life force" and means "spiritual directed life force energy". Reiki, accepted as a complementary and alternative therapy (CAM) by the National Center for Complementary and Alternative Medicine, is a simple, natural and safe method that everyone can use; It is a holistic healing method that nourishes the body, mind and spirit. The principle of Reiki is based on the principle that in case of a blockage in an energy center, disease occurs and the energy transferred by touching it strengthens and heals the body's ability to heal itself by opening the blockages. Trained Reiki practitioners can perform the application by holding their hands in certain positions on the recipient's body, as well as remotely. It will also be important for Reiki to become widespread as a nursing practice in many countries, especially for nurse candidates to experience the effects of Reiki on reducing stress and anxiety. In the literature, it is emphasized that uncontrollable test anxiety can also affect the academic success of students. For this reason, it is thought that Reiki, whose effectiveness in coping with stress and anxiety has been demonstrated by various studies, may be effective in coping with exam anxiety of nursing students. A study investigating the effect of Reiki on reducing students' anxiety could not be found in the literature. In this context, it will be the first study to examine the effect of Reiki on reducing anxiety in nursing students.

This randomized controlled prospective study was conducted with first-year nursing students between 10-19 June 2022. The data of the study was collected using "Personal Information Form I-II (PIF)" and "State Test Anxiety Scale (STAS)" via online form. Also, the final exam notes were used for assessing the success of the students, the final exam averages were used.

PIF-I and STAS were applied to the students who met the inclusion criteria and agreed to participate in the study between 10-13 June 2022. Patients were randomized 1:1 into groups by a single therapist according to the block randomization method. There were two arms in the study; Reiki treatment (n=36) and control group (n=35). A second or third-degree Reiki practitioner applied distant Reiki to the students for 20 minutes for four consecutive days (14-17 June 2022) in the Reiki treatment group. In the control group, nothing was done. At 19 June 2022, PIF- II and STAS were applied to all patients.
Venetoclax is a standard treatment for patients with chronic lymphocytic leukemia (CLL) following covalent Bruton tyrosine kinase inhibitor (cBTKi) therapy, despite relatively limited prospective data in this setting. Pirtobrutinib is a highly selective, non-covalent (reversible) BTKi that was designed to overcome the pharmacologic limitations of cBTKi and re-establish BTK inhibition. An unanchored matching-adjusted indirect comparison (MAIC) was conducted to estimate the treatment effect of pirtobrutinib versus venetoclax monotherapy in patients with cBTKi-pretreated CLL. Data from patients with CLL who were venetoclax-naïve and pretreated with cBTKi received pirtobrutinib (N=146) in the phase I/II BRUIN study were compared with the only identified trial of patients with CLL receiving venetoclax after a cBTKi (N=91), as administered as monotherapy until progression. Outcomes included progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and treatment-emergent adverse events. Both unweighted and weighted analyses were conducted. PFS and OS of pirtobrutinib and venetoclax were comparable in both unweighted and weighted analyses (weighted hazard ratios for PFS: 1.01, 95% confidence interval [CI]: 0.58-1.73, P=0.98 and OS: 0.64, 95% CI: 0.25-1.67, P=0.34). ORR was significantly higher for pirtobrutinib (80.2% vs. 64.8%, P=0.01). Grade ≥3 treatment-emergent adverse events were lower in weighted analyses for pirtobrutinib versus venetoclax (all P<0.01), except for pneumonia, which was similar. These results suggest that pirtobrutinib may also be considered as an effective and well-tolerated treatment for patients with relapsed CLL following cBTKi.
High frequency with 10 Hz at 80% motor threshold intensity with figure-of-eight coil for a total of 2,000 pulses. Pulses will be delivered in 10-second trains with a 50-second pause between the trains.
The present invention relates to shark cartilage extracts and to a method of producing the same, these extracts having anti-angiogenic properties (reduction of the area of blood vessels observed in vivo on experimentally induced tumors), tumor regressive activity in vivo as well as demonstrating a direct inhibitory effect on tumor cell lines. This process does not involve any denaturing solvent or product and does not involve the use of any enzymes. It consists of obtaining a blend of whole cartilage in an aqueous solution of neutral pH, preferably pure water, this blend being centrifuged and the pellet and supernatant kept for further processing. The pellet is lyophilized and tested for anti-tumor and anti-angiogenic activities in vivo and in vitro, with or without supernatant. The supernatant has been shown to have anti-angiogenic and tumor regressive activities in vivo. The composition of the supernatant has then been investigated by different ways. Fractionation of this supernatant led to the characterization of some of its active components. The fractions were tested for their direct in vitro activity on cancer cell lines. Therefore, it is assumed that the non-fractionated supernatant has such an in vitro activity. Lyophilization substantially destroys the activity of these liquid fractions while no such abolition is observed in the solid extract.